Despite the recent success in the development and clinical application of radiopharmaceuticals targeting the prostate-specific membrane antigen (PSMA) for diagnosis and endoradiotherapy of prostate cancer, more research is ongoing to further investigate and improve patient care and quality of life. The gene discussed is FOLH1; the disease is prostate carcinoma.